On Jul. 26, 2016, Patheon announced the closing of its initial public offering of 34,226,191 of its ordinary shares at a price of $21.00 per share with net proceeds of $584.7 million. In 2008, Patheon established its U.S. headquarters in Research Triangle Park (RTP).

In addition to the new U.S. headquarters facility, Patheon opened a new pharmaceutical development laboratory in RTP. Patheon is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry.